Author

Megan Sardone

Observed name: M. Sardone

Observed institution: Stemline Therapeutics (United States)

OpenAlex ID: A5011069584

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

2019 · Naveen Pemmaraju, Vikas Gupta, et al. · Blood · 23

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

2018 · Mrinal M. Patnaik, Haris Ali, et al. · Blood · 15

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

2018 · Naveen Pemmaraju, Vikas Gupta, et al. · Blood · 9

Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial

2024 · Simon Pacey, Ching Leung, et al. · Cancer Research · 5

Pf668 Results From Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (sl‐401) in Patients With Intermediate, or High Risk, Relapsed/refractory Myelofibrosis

2019 · N. Pemmaraju, H. Ali, et al. · HemaSphere · 5

564P Updated results of a phase I study of Felezonexor (SL-801), a novel XPO-1 reversible inhibitor, in patients with relapsed/refractory solid tumours

2020 · J.S. Wang, M.A. Barve, et al. · Annals of Oncology · 4

Interim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours

2019 · J. Wang, M. Barve, et al. · Annals of Oncology · 3

Abstract CT153: First in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors

2025 · Gerald Falchook, Jordi Rodon Ahnert, et al. · Cancer Research · 2

Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors

2023 · Udai Banerji, Simon Pacey, et al. · Molecular Cancer Therapeutics · 2

Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors.

2018 · Judy Sing-Zan Wang, Minal A. Barve, et al. · Journal of Clinical Oncology · 2

Pf672 Results From Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (sl‐401) in Patients With Relapsed/refractory Chronic Myelomonocytic Leukemia (cmml)

2019 · M. Patnaik, H. Ali, et al. · HemaSphere · 1

A phase Ib, multicenter, open-label study of NXP800, a novel GCN2 kinase activator, among patients with platinum-resistant, ARID1A-mutated ovarian cancer (ENGOT-GYN5/NCRI/NXP800-101; GOG-3087)

2024 · Susana Banerjee, Ramez Eskander, et al. · Gynecologic Oncology

Interim results from a phase I trial of SL-801: A novel XPO-1 inhibitor, in patients with advanced solid tumors

2018 · T.M. Bauer, M. Barve, et al. · Annals of Oncology

Works count: 13

Citation count: 71

H-index: 5

I10-index: 2